In addition to the expected resolution of iron deficiency (increase of mean TSAT from below to above 20%), the switch from oral iron to i.v. FCM also resulted in achievement of significantly higher Hb levels and lower ESA dose requirements at all time points during the 6-months study period (Figs 2A and 3). Here, GSTM1 is linked to Iron deficiency anemia.